Quick Answer
Climb Bio, Inc. reported Net Income of -$59.85 million for fiscal year 2025.
Climb Bio, Inc. — Key Financials by Year
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|
| Net Income | -$59.85M +19.0% |
-$73.90M -110.4% |
-$35.12M +22.4% |
-$45.24M +4.7% |
-$47.48M -129.7% |
-$20.67M |
| Diluted EPS | -$0.88 +42.5% |
-$1.53 -17.7% |
-$1.30 +24.4% |
-$1.72 +59.4% |
-$4.24 | — |
| Total Assets | $167.74M -22.8% |
$217.19M +96.6% |
$110.47M -18.2% |
$134.99M -22.1% |
$173.24M +603.3% |
$24.63M |
| Cash and Equivalents | $35.69M -59.1% |
$87.23M -6.3% |
$93.11M +113.6% |
$43.59M -7.1% |
$46.92M +129.0% |
$20.49M |
| Stockholders Equity | $160.47M -24.3% |
$211.88M +96.9% |
$107.60M -16.4% |
$128.72M -23.0% |
$167.20M +769.3% |
-$24.98M -349.2% |
| R&D Expense | $46.71M +225.8% |
$14.34M -7.0% |
$15.41M -41.2% |
$26.21M +12.4% |
$23.32M +166.0% |
$8.77M |
| Operating Income | -$67.88M +17.2% |
-$82.02M -103.6% |
-$40.27M +10.8% |
-$45.13M -26.5% |
-$35.67M -70.5% |
-$20.93M |
| Shares Outstanding | 47.77M -29.0% |
67.26M +142.8% |
27.70M +4.3% |
26.57M +0.0% |
26.57M +677.1% |
3.42M |
Most Recent Quarter
| Metric | Quarter Ending | Value | YoY | QoQ |
|---|---|---|---|---|
| Net Income | September 30, 2025 | -$12.89M | -44.9% | -48.7% |
| Diluted EPS | September 30, 2025 | -$0.19 | -46.2% | -46.2% |
| Total Assets | September 30, 2025 | $182.30M | -18.0% | -5.2% |
| Cash and Equivalents | September 30, 2025 | $25.80M | -82.3% | +13.8% |
| Stockholders Equity | September 30, 2025 | $177.00M | -19.1% | -4.7% |
| R&D Expense | September 30, 2025 | $9.07M | +45.4% | +38.0% |
| Operating Income | September 30, 2025 | -$14.89M | -26.9% | -39.5% |
| Shares Outstanding | September 30, 2025 | 68.18M | +1.4% | +0.6% |
- Climb Bio, Inc. reported Net Income of -$59.85 million for fiscal year 2025.
- Climb Bio, Inc. showed an increase of +19.0% in Net Income compared to the prior fiscal year.
- Climb Bio, Inc. reported Diluted EPS of $0.88 per share (loss) for fiscal year 2025.
- Climb Bio, Inc. showed an increase of +42.5% in Diluted EPS compared to the prior fiscal year.
- Climb Bio, Inc. reported Total Assets of $167.74 million for fiscal year 2025.
- Climb Bio, Inc. showed a decrease of -22.8% in Total Assets compared to the prior fiscal year.
- Climb Bio, Inc. reported Cash and Equivalents of $35.69 million for fiscal year 2025.
- Climb Bio, Inc. showed a decrease of -59.1% in Cash and Equivalents compared to the prior fiscal year.
- Climb Bio, Inc. reported Stockholders Equity of $160.47 million for fiscal year 2025.
- Climb Bio, Inc. showed a decrease of -24.3% in Stockholders Equity compared to the prior fiscal year.
- Climb Bio, Inc. reported R&D Expense of $46.71 million for fiscal year 2025.
- Climb Bio, Inc. showed an increase of +225.8% in R&D Expense compared to the prior fiscal year.
- Climb Bio, Inc. reported Operating Income of -$67.88 million for fiscal year 2025.
- Climb Bio, Inc. showed an increase of +17.2% in Operating Income compared to the prior fiscal year.
- Climb Bio, Inc. reported Shares Outstanding of 47.77 million shares for fiscal year 2025.
- Climb Bio, Inc. showed a decrease of -29.0% in Shares Outstanding compared to the prior fiscal year.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: